Published in Neuropsychology on November 01, 2005
Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry (2007) 2.98
Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull (2008) 1.81
What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev (2009) 1.73
Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med (2014) 1.64
Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology (2008) 1.64
Social cognitive training for schizophrenia: a meta-analytic investigation of controlled research. Schizophr Bull (2011) 1.60
Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. Am J Psychiatry (2012) 1.41
Neuropsychological near normality and brain structure abnormality in schizophrenia. Am J Psychiatry (2008) 1.29
Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. J Int Neuropsychol Soc (2008) 1.26
Impaired visual object processing across an occipital-frontal-hippocampal brain network in schizophrenia: an integrated neuroimaging study. Arch Gen Psychiatry (2010) 1.23
Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology (2010) 1.23
Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull (2009) 1.12
The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. PLoS One (2013) 1.04
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry (2007) 0.98
The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. Schizophr Bull (2008) 0.96
Auditory working memory impairments in individuals at familial high risk for schizophrenia. Neuropsychology (2012) 0.84
Memory profiles in schizophrenia: categorization validity and stability. Schizophr Res (2010) 0.82
Brain Structure in Neuropsychologically Defined Subgroups of Schizophrenia and Psychotic Bipolar Disorder. Schizophr Bull (2015) 0.78
Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study. Prostaglandins Leukot Essent Fatty Acids (2011) 0.78
Social cognitive deficits in schizophrenia and their relationship to clinical and functional status. Psychiatry Res (2012) 0.77
Neurocognitive Decrements are Present in Intellectually Superior Schizophrenia. Front Psychiatry (2014) 0.77
The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. NPJ Schizophr (2015) 0.75
Cortical Thinning in Network-Associated Regions in Cognitively Normal and Below-Normal Range Schizophrenia. Schizophr Res Treatment (2017) 0.75
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry (2007) 4.44
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry (2007) 2.98
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation (2002) 2.32
Intact attentional control of working memory encoding in schizophrenia. J Abnorm Psychol (2006) 2.28
Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry (2004) 2.27
Patients with schizophrenia demonstrate dissociation between affective experience and motivated behavior. J Abnorm Psychol (2007) 2.08
A new perspective on anhedonia in schizophrenia. Am J Psychiatry (2012) 2.08
Depressive symptoms and heart rate variability in postmenopausal women. Arch Intern Med (2005) 2.08
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr Res (2007) 1.98
Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (2009) 1.95
Delay discounting in schizophrenia. Cogn Neuropsychiatry (2007) 1.94
Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics (2002) 1.92
Anticipatory vs. consummatory pleasure: what is the nature of hedonic deficits in schizophrenia? Psychiatry Res (2011) 1.91
General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry (2008) 1.86
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res (2005) 1.73
Failure of schizophrenia patients to overcome salient distractors during working memory encoding. Biol Psychiatry (2010) 1.73
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res (2005) 1.69
The construct of attention in schizophrenia. Biol Psychiatry (2008) 1.68
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
General and specific cognitive deficits in schizophrenia. Biol Psychiatry (2004) 1.64
Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology (2008) 1.64
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol Psychiatry (2010) 1.58
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
Decision-making impairments in the context of intact reward sensitivity in schizophrenia. Biol Psychiatry (2008) 1.55
A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull (2013) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res (2006) 1.49
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39
Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull (2006) 1.39
Galantamine-induced QTc prolongation. J Clin Psychiatry (2006) 1.38
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry (2009) 1.36
Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry (2002) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull (2005) 1.34
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Schizophrenia in translation: the presence of absence: habenular regulation of dopamine neurons and the encoding of negative outcomes. Schizophr Bull (2006) 1.33
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res (2004) 1.33
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res (2008) 1.30
Optimization of a goal maintenance task for use in clinical applications. Schizophr Bull (2012) 1.30
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull (2006) 1.30
Patients with schizophrenia demonstrate inconsistent preference judgments for affective and nonaffective stimuli. Schizophr Bull (2010) 1.29
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
The speed of visual attention in schizophrenia: electrophysiological and behavioral evidence. Schizophr Res (2006) 1.26
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
Optimization and validation of a visual integration test for schizophrenia research. Schizophr Bull (2011) 1.26
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology (2010) 1.23
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Impaired response selection in schizophrenia: evidence from the P3 wave and the lateralized readiness potential. Psychophysiology (2009) 1.23
Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr Bull (2006) 1.21
Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls. Schizophr Bull (2010) 1.21
Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology (2011) 1.21
Relational and Item-Specific Encoding (RISE): task development and psychometric characteristics. Schizophr Bull (2011) 1.21
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2011) 1.20
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (2010) 1.19
Impaired control of visual attention in schizophrenia. J Abnorm Psychol (2006) 1.19